MK-5684

PreclinicalSmall molecule

MK-5684 is one of 6 small molecule programs targeting Castration Resistant Prostatic Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Castration Resistant Prostatic CancerRecruiting

Castration Resistant Prostatic CancerPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Castration Resistant Prostatic Cancer

#DrugCompanyPhaseTrials

Xtandi

Astellas

Preclinical

1 2

Taxotere

AAvyxa

Preclinical

1 3

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 4

Rescue Medication

Merck & Co.

Preclinical

1 5

Opevesostat

Merck & Co.

Preclinical

1 6

MK-5684

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

PreclinicalRecruiting

Castration Resistant Prostatic Cancer

NCT06863272

Clinical

Trials by Indication[1]

End Stage Renal Disease (ESRD)1 trial

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06814132·24 enrolled

Interaction1 trial

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06554639·12 enrolled

Castration Resistant Prostatic Cancer1 trial

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06863272·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MK-5684. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-5684 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-5684. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Merck & Co.

MK-5684

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

End Stage Renal Disease (ESRD)1 trial

Interaction1 trial

Castration Resistant Prostatic Cancer1 trial

References

Drug Info

Quick Facts

Related News